{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:37:13Z","timestamp":1794379033023,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01494-z","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T03:29:36Z","timestamp":1753241376000},"page":"2819-2832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)"],"prefix":"10.1007","volume":"15","author":[{"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brnabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Boy\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"1","key":"1494_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35\u201355.","journal-title":"BioDrugs"},{"key":"1494_CR2","doi-asserted-by":"publisher","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","volume":"102","author":"ME Van Muijen","year":"2022","unstructured":"Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, et al. Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort. Acta Derm Venereol. 2022;102:adv00712.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1494_CR3","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"1494_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","volume":"308","author":"C Blome","year":"2016","unstructured":"Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69\u201378.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1494_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jdv.15324","volume":"33","author":"JT Maul","year":"2019","unstructured":"Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1494_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1494_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjd.20387","volume":"185","author":"JT Maul","year":"2021","unstructured":"Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185(6):1160\u20138.","journal-title":"Br J Dermatol"},{"key":"1494_CR8","doi-asserted-by":"publisher","first-page":"adv20329","DOI":"10.2340\/actadv.v104.20329","volume":"104","author":"JT Maul","year":"2024","unstructured":"Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, et al. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis: a cross-sectional global healthcare study on psoriasis. Acta Derm Venereol. 2024;104:adv20329.","journal-title":"Acta Derm Venereol"},{"key":"1494_CR9","doi-asserted-by":"publisher","first-page":"adv42296","DOI":"10.2340\/actadv.v105.42296","volume":"105","author":"R Lichtenberger","year":"2025","unstructured":"Lichtenberger R, Maul LV, Birkenmaier I, Oyanguren I, Ak M, Heidemeyer K, et al. Sex disparities of health-related quality of life in moderate to severe psoriasis: a real-world analysis from the Swiss Psoriasis Registry (SDNTT). Acta Derm Venereol. 2025;105:adv42296.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1494_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/jdv.18376","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Puig L, Schakel K, Reich A, Zaheri S, Costanzo A, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u2013100.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1494_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s13555-023-01086-9","volume":"14","author":"A Pinter","year":"2024","unstructured":"Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, et al. Comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatol Ther (Heidelb). 2024;14(6):1479\u201393.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1494_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12325-024-03034-1","volume":"42","author":"S Khattri","year":"2025","unstructured":"Khattri S, Gonzalez-Cantero A, Engin B, Dogra S, Murphy CA, Schuster C, et al. Comparative effectiveness of biologic classes in clinical practice: month 12 outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). Adv Ther. 2025;42(1):233\u201345.","journal-title":"Adv Ther"},{"issue":"5","key":"1494_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hernan","year":"2000","unstructured":"Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561\u201370.","journal-title":"Epidemiology"},{"issue":"4","key":"1494_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/aje\/kwaa225","volume":"190","author":"C Leyrat","year":"2021","unstructured":"Leyrat C, Carpenter JR, Bailly S, Williamson EJ. Common methods for handling missing data in marginal structural models: what works and why. Am J Epidemiol. 2021;190(4):663\u201372.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"1494_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology"},{"key":"1494_CR16","unstructured":"European Medicines Agency. Psoriasis Study of Health Outcomes\u2014an international observational study of 3 year health outcomes in the biologic treatment of moderate to severe plaque psoriasis. ENCePP. https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=25115. EUPAS24207. 2018. Accessed 20 May 2025."},{"issue":"8","key":"1494_CR17","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, Augustin M, Neupane B, Kazmierska P, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777\u201392.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1494_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gooderham M, Griffiths CEM, Armstrong AW, Zhu B, Burge R, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(3):727\u201340.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1494_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13555-019-00337-y","volume":"10","author":"RB Warren","year":"2020","unstructured":"Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73\u201386.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1494_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","volume":"33","author":"N Yasmeen","year":"2022","unstructured":"Yasmeen N, Sawyer LM, Malottki K, Levin LA, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2022;33(1):204\u201318.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1494_CR21","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1111\/jdv.20555","volume":"39","author":"RG Langley","year":"2025","unstructured":"Langley RG, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, et al. Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2025;39(7):e613\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1494_CR22","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023;34(1):2200870.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"1494_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1517\/14712598.2013.848194","volume":"13","author":"C De Simone","year":"2013","unstructured":"De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, et al. Immunogenicity of anti-TNFalpha therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673\u201382.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1494_CR24","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s13555-024-01258-1","volume":"14","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Blauvelt A, Sima AP, Beaty SW, Low R, Gomez B, et al. Impact of disease factors of patients with psoriasis and psoriatic arthritis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2024;14(10):2805\u201325.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1494_CR25","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s12325-021-01698-7","volume":"38","author":"M Skornicki","year":"2021","unstructured":"Skornicki M, Prince P, Suruki R, Lee E, Louder A. Clinical burden of concomitant joint disease in psoriasis: a US-Linked Claims and Electronic Health Records Database Analysis. Adv Ther. 2021;38(5):2458\u201371.","journal-title":"Adv Ther"},{"issue":"2","key":"1494_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12789","volume":"32","author":"F Dabouz","year":"2019","unstructured":"Dabouz F, Khemis A, Barbe C, Lahfa M, Maccari F, Chaby G, et al. Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study. Dermatol Ther. 2019;32(2): e12789.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1494_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-025-01342-0","volume":"15","author":"D Thaci","year":"2025","unstructured":"Thaci D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: Interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther (Heidelb). 2025;15(2):381\u201394.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01494-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01494-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01494-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:21:57Z","timestamp":1758720117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01494-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1494"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01494-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andreas Pinter has served as an investigator, speaker and\/or consultant for AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, Leo Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough and UCB Pharma. Emanuele Trovato has served as speaker for AbbVie, Novartis, Janssen, UCB Pharma, Eli Lilly and Company, Almirall and Leo Pharma. Llu\u00eds Puig reports grants to institution from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo Pharma, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB, has received consulting fees or honoraria from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Eli Lilly and Company, Merck Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB and participated in company-sponsored speaker\u2019s bureau for Celgene, Janssen, Eli Lilly and Company, MSD, Novartis and Pfizer. Jose-Manuel Carrascosa reports grants, personal fees, participation on advisory boards and\/or nonfinancial support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Eli Lilly and Company, Janssen, Novartis, Sandoz and Leo Pharma. Llu\u00eds Puig and Jose-Manuel Carrascosa are Editorial Board Members of Dermatology and Therapy. Llu\u00eds Puig and Jose-Manuel Carrascosa were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Thierry Boy\u00e9 reports personal fees and grants (clinical research) from Novartis, Leo Pharma, Janssen, AbbVie, Amgen, Eli Lilly and Company and UCB. Matteo Megna declares to have acted as speaker and\/or consultant for AbbVie, Amgen, Almirall, Eli Lilly and Company, Janssen-Cilag, Leo Pharma, Novartis and UCB. Julia-Tatjana Maul has served as advisor and\/or received speaking fees and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly and Company, Leo Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi and UCB. Alan Brnabic, Silvia Sabatino and Inmaculada De La Torre are employees and minor shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol, amendments and consent documentation were approved by local institutional review boards (IRB). A complete list of the ethical review board committees is available in the supplementary materials accompanying this study (see Supplementary Table S7: Ethical Review Boards). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) [] and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and\/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}